Discovery and Evaluation of Novel Adjuvants for Vaccine Formulations
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Physical Pharmacy and Formulation".
Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 84544
Special Issue Editors
Interests: nanomedicine; nanoparticle toxicology; nanocarriers for pulmonary/nasal delivery (small molecules and macromolecules/vaccines); smart responsive nanocarriers
Special Issues, Collections and Topics in MDPI journals
Interests: nanoparticles; vaccines; mucosal administration; immunotherapy; nanomedicine
Special Issue Information
Dear Colleagues,
Vaccination has been a key strategy for the prevention and treatment of numerous pathologies worldwide. The development of vaccines incorporating only certain components of pathogens, such as the protein, sugar or capsid, has resulted in formulations capable of inducing immune responses of greater specificity, with fewer side effects. However, due to the lower immunogenicity of such components, adjuvants are required for the induction of sufficient immune responses. Adjuvants such as alum have been in clinical use for 100 years, but with the advancements in the understanding of the immune system and high throughput discovery methods for identifying potential candidates, a new generation of novel adjuvants with high efficacy and simultaneous safety are possible. This Special Issue will highlight aspects associated with novel vaccine adjuvants, through the stages of discovery, screening, evaluation, and incorporation as formulations.
Prof. Imran Saleem
Dr. Kan Kaneko
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- adjuvant
- vaccine
- drug discovery
- screening
- nanotechnology
- subunit vaccine
- immune stimulation
- immunotherapy